CorMedix (CRMD) Stock News
$CRMD · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on CorMedix (CRMD) in the past 30 days, 1 of it high impact. BORSA’s news read on CRMD is bullish at 62/100, based on 2 company events over the past 7 days. CRMD last closed at $4.84 on Nov 12, down 7.46% over five sessions and down 34.51% over the past month.
The wire on $CRMD
newest first · updated · direct subject stories onlyCorMedix Therapeutics reported Q3 revenue of $54.5M (above $51.2M consensus), net loss of $14.7M, and adjusted EBITDA of $3.1M. The company maintained FY2026 revenue guidance of $325-345M and narrowed adjusted EBITDA guidance to $130-140M. It suspended 2027 DefenCath revenue guidance due to CMS reimbursement changes. The pending Heron Therapeutics acquisition and REZZAYO sNDA review remain key catalysts.
neutral 50 · impact 70Earlier $CRMD stories: November 2026
The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.
CorMedix (CRMD) stock: common questions
What is the latest CorMedix stock news?
The highest-impact CRMD story BORSA published in the past 30 days: